Using a “double whammy” of 2 HER2-directed therapies achieved a clinical benefit rate of 70% and an objective response rate (ORR) of 30% in patients with heavily pretreated, HER2-positive metastatic colorectal cancer (CRC), according to final results from the phase 2 HERACLES-A trial.
Adding vemurafenib to cetuximab and irinotecan prolonged progression-free survival (PFS) and improved the disease control rate in patients with BRAF V600E mutation–positive colorectal cancer (CRC).
Church and Academia Collaborate on an Educational Program to Increase Colorectal Cancer Screening (EPICS) in African Americans
Tierra Amos, BS, Thomas Britt, MD, MPH, Gina Curry, BSPH, Robyn Espinosa, BS, Sheila Mahon, BS, Juned Mohammed, BDS, Yashika Watkins, PhD, MPH
Partnerships between churches and universities have emerged as a promising approach for addressing public health inequities. EPICS is a community outreach and screening program.
At the Sixth Annual Academy of Oncology Nurse & Patient Navigators Conference in Atlanta, GA, Noel Kinard, LMSW, Oncology Social Worker, Gibbs Cancer Center & Research Institute, Spartanburg, SC, discussed how to navigate barriers to care for patients with colorectal cancer and who require screening, how to best support these patients, and the current controversies in colorectal cancer care.